A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT06554600 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Refractory or Relapsed Diffuse Large B Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Polatuzumab Vedotin
DRUG: Bendamustine
DRUG: Rituximab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University